| Human mycoses and current antifungal therapy. | |
| | |
MedLine Citation:
|
PMID: 15616619 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
The Focus on Fungal Infections meeting has become a popular conference for specialists in medical mycology and antifungal chemotherapy. Highlights of the 8th meeting are reported, with a focus on infection and therapy. Although the incidence of mycoses has increased, the identification of these fungal etiologic agents remains difficult. Mucosal candidiasis caused by endogenous Candida albicans and Candida species remains the most common fungal manifestation in HIV-infected patients, while systemic infection by Aspergillus species also has increased in HIV patients. Two presenters at the meeting debated whether fungal infections in AIDS patients are becoming less common and less important. Various strategies for antifungal therapy in AIDS or HIV-positive patients were presented. Most fungal infections in solid organ transplant patients are due to Candida species or Aspergillus species; however, dematiaceous (dark-pigmented) fungi are becoming more common fungal pathogens in these patients. Antifungal therapy remains difficult in this patient group. The meeting included an overview of the current status of diagnosing fungal infections through serodiagnostic techniques. If properly validated, serology can be useful in fungal diagnosis since antigens and antibodies are easier to detect than the invading organism. Premature infants are at high risk for developing invasive fungal infections. Antifungal drugs have not been tested in controlled clinical trials in these patients, thus therapy is accomplished using adult treatment regimens and anecdotal experience. As regards the new lipid-based formulations of amphotericin B, published clinical studies are only now appearing in the literature and these reports suggest that the new formulations have reduced toxicity and comparable efficacy compared to conventional amphotericin B under various clinical conditions. Correlation of minimum inhibitory concentration (MIC) values with clinical response to therapy is beginning to emerge. Two fungal cell wall-active compounds have recently entered clinical trials: an echinocandin and the chitin-synthesis inhibitor nikkomycin Z. Pradimycin and analogues have been studied through experimental animal models with good success; however, phase I clinical trials suggested drug-related toxicities and development was stopped. New molecular targets also are being investigated in antifungal therapy. |
| | |
Authors:
|
R A Fromtling |
Related Documents
:
|
15367919 - Fcgamma receptor iia genotype and susceptibility to p. aeruginosa infection in patients... 23234349 - Kwazulu-natal minibus taxi drivers' perceptions on hiv and aids: transmission, preventi... 2537909 - Signet cell carcinoma of the stomach in a patient with acquired immunodeficiency syndro... 15040519 - Prevalence of hiv among women with vaginal discharge in a gynecological clinic. 10865899 - Disseminated penicillium marneffei infection in an hiv-positive female from thailand in... 13680169 - Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the i... 9670619 - Risk factors in the transmission of leptospiral infection. 2379789 - Cimetidine and omeprazole have different effects on hepatic extraction of lidocaine in ... 8903369 - The clinical significance of changes in genetic heterogeneity of the hypervariable regi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Drug news & perspectives Volume: 11 ISSN: 0214-0934 ISO Abbreviation: Drug News Perspect. Publication Date: 1998 Apr |
Date Detail:
|
Created Date: 2004-12-23 Completed Date: 2005-03-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8809164 Medline TA: Drug News Perspect Country: Spain |
Other Details:
|
Languages: eng Pagination: 185-91 Citation Subset: - |
Copyright Information:
|
(c) 1998 Prous Science. All rights reserved. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Idea management: restructuring technology-based research to help achieve corporate goals.
Next Document: Reducing pharmaceutical risk.